FOSUN HEALTH Logo

Our Parent Company – Fosun Pharma

Fosun Health Hospitals is part of Fosun Health, the medical services arm of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”), which is dual-listed on the Shanghai and Hong Kong stock exchanges and brings global healthcare standards, governance, and scientific innovation to patient care.

Who Is Fosun Pharma?

Fosun Pharma headquarters building

Founded in 1994, Fosun Pharma is an innovation-driven, globally integrated healthcare group operating across pharmaceuticals, medical devices & diagnostics, and healthcare services — a combination few hospital groups worldwide can match.

For more than 30 years, Fosun Pharma has invested in R&D across the United States, Europe, Africa, India and Southeast Asia, anchored on oncology, immunology & inflammation, and neurodegenerative diseases. Fosun Health, the holding company behind the hospitals on this website, is a subsidiary of Fosun Pharma. The care you receive here is governed by the same standards, governance and clinical resources as one of Asia's most respected healthcare groups.

Fosun Pharma key figures

Breakthrough Therapies, Delivered at Our Hospitals

In 2025 alone, seven innovative drugs covering 16 indications were approved in China and abroad, and nearly 40 clinical trials were authorized in China, the U.S., and the EU. Some of these breakthroughs — including the world's first approved solid-tumor CAR-T therapy — are now being delivered to patients at our own hospitals.

Beyond these, Fosun Pharma invests in radiopharmaceuticals, RNA therapeutics, gene editing, ADCs, and AI-powered drug discovery — translating frontier science into clinical practice.

A Truly Global Network

Fosun Pharma's operations span six continents, giving Fosun Health hospitals access to internationally sourced expertise, equipment, and clinical collaboration—and giving international patients a seamless pathway to care in China.

Explore Our Global Network

Fosun Health: The Medical Services Arm of Fosun Pharma

Fosun Health, founded in 2010, is a holding subsidiary of Fosun Pharma (SSE 600196 / HKEX 02196). It unifies general and specialty hospitals across China into a single platform that integrates online and offline care — and it is the parent organization of the hospitals you can visit through this website.

Why The Parent Company Matters To You

  1. Financial Stability

    RMB 41.66 billion in annual revenue and dual-exchange listing mean our hospitals are backed by a financially strong, publicly accountable group.

  2. Access to Cutting-Edge Therapies

    From the world's first solid-tumor CAR-T to robotic surgery, our patients can access therapies developed or brought to market by our parent group.

  3. Internationally Certified Quality

    The group's 17 GMP-certified production lines and dual GCP-certified hospitals reflect a single, international quality culture that extends to clinical care.

  4. Research-Driven Care

    Being part of China's No. 1 group for international multi-center clinical trials means our doctors practice at the frontier of global medicine.

Listed, Audited, Globally Recognized

Public listing means transparency. Every figure on this page comes from Fosun Pharma's audited FY2025 annual report, published on both the Shanghai and Hong Kong exchanges.

Frequently Asked Questions

Is Fosun Pharma a listed company?

Yes. Fosun Pharma is dual-listed on the Shanghai Stock Exchange (SSE: 600196) and the Hong Kong Stock Exchange (HKEX: 02196). It publishes audited annual reports and is subject to regulatory oversight in both markets — a level of transparency you can verify directly.

How is Fosun Pharma related to Fosun Health Hospitals?

Fosun Health is the medical services arm of Fosun Pharma. The hospitals featured on this website belong to Fosun Health, a holding subsidiary of Fosun Pharma — so they operate under the group's quality standards, governance and clinical resources.

Does Fosun Pharma operate internationally?

Yes. Fosun Pharma operates across China, the United States, Europe, Africa, India and Southeast Asia. In FY2025, overseas revenue accounted for 31.15% of total revenue, and its Africa marketing network alone covers more than 40 countries.

What innovative therapies has Fosun Pharma brought to patients?

Highlights include Yikaida® (China's first approved CAR-T), Kailimei® (the world's first approved solid-tumor CAR-T, delivered at Fosun Health hospitals), Serplulimab (the first PD-1 approved in the EU for first-line extensive-stage small cell lung cancer, now in 40+ countries), and Artesun® (WHO-recommended severe malaria treatment used by more than 56 million patients).

Experience Fosun Health, Backed by Fosun Pharma

From world-first CAR-T therapy to robotic surgery, our hospitals bring the innovation of a global healthcare leader directly to you. Let our international patient services team design your care journey.

Book A Free Remote Consultation Who We Are — Network & Milestones

Follow Fosun Health

Apply for an Appointment

Do you have test results*